Department of Biotechnology

The Department of Biotechnology (DBT) was established in 1986 as a separate department within the Ministry of Science and Technology, making India one of the first countries to create a dedicated administrative apparatus for biotechnology. It functions alongside the Department of Science and Technology (DST) and the Department of Scientific and Industrial Research (DSIR) under the same ministry. The DBT's mandate spans agricultural, medical, environmental, and industrial biotechnology, and it serves as the nodal department for implementing India's national biotechnology policy and for coordinating the country's position in international biosafety and bioresource frameworks, including the Cartagena Protocol on Biosafety (2000) and the Nagoya Protocol on Access and Benefit-Sharing (2010).

The DBT operates through an extensive institutional ecosystem. It funds and oversees autonomous research institutes such as the National Institute of Immunology (NII), the National Centre for Cell Science (NCCS), the National Brain Research Centre (NBRC), and the Centre for DNA Fingerprinting and Diagnostics (CDFD). Its public-sector undertaking, the Biotechnology Industry Research Assistance Council (BIRAC), launched in 2012, catalyses industry-academia innovation and administers schemes like the Biotechnology Ignition Grant (BIG). The DBT also administers regulatory functions under the Environment (Protection) Act, 1986, and the 1989 Rules: the Review Committee on Genetic Manipulation (RCGM) operates under DBT, while the Genetic Engineering Appraisal Committee (GEAC) sits under the Ministry of Environment, Forest and Climate Change—a distinction frequently tested. Flagship DBT programmes include the Genome India Project, the Indian Biological Data Centre (IBDC) at Faridabad, the National Biopharma Mission (Innovate in India, i3), and the Ind-CEPI mission for epidemic preparedness.

The DBT played a visible role during the COVID-19 pandemic, supporting indigenous vaccine development including the DNA vaccine ZyCoV-D and contributing to the Mission COVID Suraksha vaccine-development consortium. Its policy outputs include the National Biotechnology Development Strategy and, more recently, the push toward a "bioeconomy" framework—India's BioE3 (Biotechnology for Economy, Environment and Employment) Policy was approved by the Union Cabinet in August 2024 to promote high-performance biomanufacturing. The DBT also operates the Biosafety Clearance mechanism for genetically modified organisms and supports the Rashtriya Gene Bank and biodiversity conservation initiatives. As of 2026 the department continues to anchor India's stated goal of expanding the bioeconomy substantially through biomanufacturing hubs and synthetic biology.

For the UPSC examination, the DBT appears primarily in the General Studies Paper III section on science and technology—particularly in questions on biotechnology applications in health and agriculture, regulatory architecture for GM crops, and India's institutional science framework. The most common question angle distinguishes the roles of DBT (research promotion and RCGM) from the GEAC under MoEFCC (final environmental clearance for GMO release), a separation often confused by candidates. Prelims may test the parent ministry, the year of establishment (1986), associated bodies such as BIRAC, and specific missions like the Genome India Project or the BioE3 Policy. Aspirants should connect the DBT to broader themes of self-reliance (Atmanirbhar Bharat) in vaccines, bio-pharmaceuticals, and the emerging bioeconomy.